LPTI Longport Inc (CE)

Longport, Inc. (OTC PK: LPTI), a medical technology specialist in high-frequency high resolution ultrasound imaging, today announced that it had made sales of its EPISCAN system into the transitional care / rehabilitation and the acute hospital sectors for pressure ulcer prevention and wound assessment. Longport�s EPISCAN system has the capability to detect deep tissue injury at the time of a patient�s admission to the hospital which helps to determine where a pressure ulcer originates. The sale into the acute hospital sector was stimulated by the CMS rule change described in Longport�s announcement dated September 20, 2007 and entitled �CMS to Stop Reimbursement for Hospital Acquired Pressure Ulcers�. This CMS rule change has been widely reported in the media and is expected to benefit Longport�s efforts in getting the Company�s EPISCAN I-200 ultrasound scanner accepted in hospitals for use in pressure ulcer prevention. The images the scanner generates help facilities see the early stages of deep tissue injury and thus initiate targeted preventative intervention earlier, which can frequently prevent pressure ulcers developing. In 2008, Longport has also sold EPISCAN systems to a wound care provider as well making continued sales into long term care for pressure ulcer prevention. Paul Wilson, President of Longport commented, �Longport is pleased to report the increased sales activities from a range of customer groups associated with pressure ulcer prevention and wound assessment. These sales reflect a significant increase in inquiries received and quotations issued during the last four months from prospective customers looking for new technology to document, prevent, and assess pressure ulcers, as well as to reduce their potential liability to sanctions and litigation.� About Longport, Inc. Longport, Inc. of Glen Mills, Pennsylvania, is a medical technology company that specializes in high resolution ultrasound imaging. After several years and a multi-million dollar investment in the technology, Longport has secured patents, copyrights and FDA permission to market. The Company�s technology has been used to engineer a unique high resolution ultrasound imaging system. For further information please contact Longport, Inc. at 1-800-289-6863 or visit our website at www.longportinc.com. Forward-looking Information and the Private Securities Litigation Reform Act of 1995 Certain statements in this press release, including statements concerning product development milestones and anticipated events, are �forward-looking statements� within the Private Litigation Reform Act of 1995. Forward Looking Statements are based on the opinions and estimates of management at the time the statements are made and are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. The words �believe,� �expect,� �intend,� �anticipate,� variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could affect Longport�s actual results include, among others, uncertainties as to the Company�s ability to manage potential problems, delays or anticipated expenses, including problems, delays or expenses involving manufacturing. Readers are cautioned not to place undue reliance upon these forward-looking statements that speak only to the date of this release. Reference is made to Longport�s 2004 annual report on Form 10-K filed with the Securities and Exchange Commission for a more definitive description of such factors. Longport, Inc. undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.